Radiolabeled Cationic Steroid Antimicrobials for Infection Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack effective tools for accurately detecting and imaging infections and hyperproliferative disorders such as tumors and cancers, particularly those resistant to conventional therapies, with a need for non-toxic and stable compounds that can selectively target bacterial and viral membranes.
Innovation Solution
Development of detectably labeled cationic steroid antimicrobials (CSAs), specifically CSA-13, which are radiolabeled with technetium-99m, rhenium-186, or rhenium-188, allowing for binding to infections and tumors, enabling diagnostic and imaging techniques through their ability to disrupt cell membranes and remain stable for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then existing diagnostic tools are available, but they lack effectiveness in accurately detecting infections and hyperproliferative disorders
Solution Approach 1:
The patent modifies the chemical structure of steroid compounds by introducing cationic groups and radiolabels, transforming them into detectably labeled cationic steroid antimicrobials (CSAs). This parameter change enables the compounds to selectively bind to negatively charged bacterial and viral membranes, providing accurate detection of infections and tumors through imaging techniques.
Solution Approach 2:
The invention combines multiple functional components into a single composite molecule: the steroid backbone provides membrane affinity, cationic groups enable electrostatic attraction to negatively charged membranes, and radiolabels (such as technetium-99m, rhenium-186, or rhenium-188) provide detectability. This composite structure allows simultaneous binding to target membranes and detection via imaging.
2Measurement precision
If compounds with high membrane binding affinity are used, then selective targeting of bacterial and viral membranes is achieved, but toxicity to host cells may increase
Solution Approach 1:
The cationic steroid antimicrobials exhibit local quality in their interaction with membranes: they selectively bind to and disrupt bacterial and viral membranes while showing minimal toxicity to host cells. This selective local action is achieved through the compound's ability to preferentially interact with the unique composition and charge distribution of pathogenic membranes versus host cell membranes.
Solution Approach 2:
By modifying the charge and chemical properties of the steroid compound, the invention changes its interaction parameters with different membrane types. The cationic groups enable selective binding to negatively charged pathogenic membranes while the modified structure reduces non-specific interactions with host cell membranes, thereby maintaining selectivity while reducing toxicity.
3Loss of information
If radiolabeling is applied to CSAs, then diagnostic and imaging capabilities are enabled, but compound stability may be affected
Solution Approach 1:
The patent employs chelating agents as intermediaries to bind radiometals to the cationic steroid antimicrobial molecules. These chelators serve as stable linkers that maintain the radiolabel attached to the CSA throughout the diagnostic period, preventing premature dissociation while allowing the compound to maintain its membrane-binding and disruptive functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The labeled CSAs effectively bind to bacterial and viral membranes, providing clear diagnostic and imaging capabilities for infections and tumors, offering a non-toxic and stable solution for detecting and imaging infections and hyperproliferative disorders with high specificity and stability.
Implementation Method 1
These compounds have a net positive charge that is electrostatically attracted to the negatively charged cell membranes of certain viruses, fungi and bacteria.
Implementation Method 2
The detectable label comprises a radioisotope selected from the group consisting of 99m
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA- 13 labeled with 99mTc is used to detect the presence of an infection.